QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pesaturo, A. B Articles by Voils, S. A Search for Related Content PubMed PubMed Citation Articles by Pesaturo, A. B Articles by Voils, S. A

CRITICAL CARE

Terlipressin: Vasopressin Analog and Novel Drug for Septic Shock

Pharmacy Practice Resident, Department of Pharmacy Services, Saint Joseph Healthcare, Inc., Lexington, KY

Heath R Jennings, PharmD BCPS

Clinical Pharmacy Specialist, Department of Pharmacy Services, Saint Joseph Healthcare, Inc.

Stacy A Voils, PharmD BCPS

Critical Care Specialist, Neurosurgery, and Clinical Assistant Professor, Virginia Commonwealth University, Medical College of Virginia Hospitals, Department of Pharmacy Services, Richmond, VA

Reprints: Dr. Voils, Virginia Commonwealth University, Medical College of Virginia Hospitals, Department of Pharmacy Services, 401 N. 12th St., PO Box 980042, Richmond, VA 23298-0042, svoils{at}mcvh-vcu.edu

OBJECTIVE: To review and assess available literature on chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical studies, adverse events, drug interactions, and dosing and administration of terlipressin in septic shock.

DATA SOURCES: A literature search of MEDLINE (1966-September 2006), International Pharmaceutical Abstracts (1970-September 2006), and Cochrane database (third quarter 2006) was conducted, using key terms of terlipressin, lypressin, triglycyl-lysine vasopressin, hemodynamic support, septic shock, vasopressor, and V1 receptor agonist. Bibliographies of relevant articles were reviewed for additional references.

STUDY SELECTION AND DATA EXTRACTION: Available English-language literature, including abstracts, animal studies, preclinical studies, clinical trials, and review articles, were examined.

DATA SYNTHESIS: Because of potentially favorable pharmacokinetics versus vasopressin and limited availability of vasopressin in some countries, the effects of terlipressin, a vasopressin analog, have been studied recently for the treatment of septic shock. When administered as a 1-2 mg intravenous dose in patients with septic shock, terlipressin increases mean arterial pressure, urine output, systemic vascular resistance index, pulmonary vascular resistance index, and left and right ventricular stroke work index while decreasing heart rate, cardiac output, lactate, and oxygen delivery and consumption index. It is unclear whether lower doses of terlipressin would produce a similar vasopressor response with fewer cardiopulmonary effects and whether the effects of the drug on oxygen transport indices are detrimental.

CONCLUSIONS: Terlipressin is a promising investigational medication for treatment of septic shock. Small trials have shown terlipressin to have favorable effects on hemodynamics in patients with septic shock refractory to conventional vasopressor treatment. It should be used with extreme caution in patients with underlying cardiac or pulmonary dysfunction. Further studies are needed to verify safety, efficacy, and dosing of terlipressin in patients with septic shock, and its use cannot be recommended in lieu of vasopressin at this time.

Key Words: septic shock, terlipressin

Published Online, December 5, 2006. www.theannals.com, DOI 10.1345/aph.1H373

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-030-H01

This article has been cited by other articles:

				S. L. M. Mitchell and J.M. Hunter Vasopressin and its antagonists: what are their roles in acute medical care? Br. J. Anaesth., August 1, 2007; 99(2): 154 - 158. [Full Text] [PDF]